Introduction
One hundred years after its commercial launch ide of salicylyl alcohol) which is doubly a pro-drug of salicylic acid. Hoffmann's search for a pro-drug as 'Bayer Aspirin', acetyl salicylic acid (2-acetoxypresentation of salicylic acid which would be reliably benzoic acid) must be the most widely used absorbed and tolerable in the large doses required medication in the world. Since our experience is for analgesia unwittingly gave us a new drug, aspirin, that half or more of the elderly population of the UK with clinical actions and a specific pharmacological is now taking regular, low-dose aspirin, either preactivity which are quite separate from the activities scribed by a doctor or self-prescribed, we have of the salicylic acid to which it is readily converted reviewed the balance of clinical benefit and risk of in the body. aspirin use. We have reviewed particularly data from blinded randomized efficacy trials, but refer to other sources. Our specific objective has been to assess Clinical pharmacology of aspirin the bleeding associated with aspirin use and to balance this with the benefits in prevention of Aspirin is readily hydrolysed to yield salicylic acid,2,3 vascular disease.
in the gut to a small extent, during transit through Over a century before Hoffmann developed a the gut wall, more rapidly during first-pass metabolprocess for bulk preparation of stable acetyl salicylic ism in the liver, as a concomitant of acetylation of acid (the compound had been first documented in plasma and other proteins, and by plasma hydrolases. 18531), the Reverend Edward Stone wrote from There is some evidence that, particularly at lower Chipping Norton on April 25th, 1763, to the then aspirin dosages, the platelet inhibitory effect is President of the Royal Society the following: 'There inversely correlated with hydrolysis rate in plasma.4 is the bark of an English tree, which I have found At all doses, systemic exposure to salicylate is by experience to be a powerful astringent, and very considerably greater than for aspirin itself, since the efficacious in curing anguish and intermitting dishalf life of aspirin in blood is less than 20 min, while orders.' The active principle in infusions of willow that of salicylate is rather more than 2 h.5 Aspirin ingestion leads rapidly to inhibition of bark was later characterized as saligenin (the glucos-platelet aggregation and prolongation of skin bleedearly platelet aggregates. PGH 2 is also the precursor in gastric mucosa for the cytoprotective and vasodilaing time.6 Several days are required for these haemostatic functions to return to pre-ingestion levels, as tory PGE 2 ; in inflammatory cells of PGE 1 which sensitizes nociceptors to pain signals, and for a host the platelet, having no nucleus, cannot replace inhibited enzymes and recovery is dependent on the of other mediators and effectors (see e.g. Hawkey and Rampton2). rate of new platelet formation: the bleeding time recovers more quickly. The substantial literature on Platelets and polymorphonuclear cells also possess 12-lipoxygenase (12-LO) activity. The stable product the influence of dose, timing and formulation on aspirin's pharmacodynamic effects has not been of 12-LO action, 12-hydroxyeicosatetraenoic acid (12-HETE), is implicated in platelet adhesion and systematically reviewed recently, but several papers give a feel for the complexities.7-10 An adequate spreading on subendothelial matrix and vascular endothelial cells. It is thus a key substance in the dose, generally >100 mg single dose rapidly absorbed, or >40 mg daily, will result in a rapid formation both of haemostatic plugs and arterial thrombi and, a fortiori, in the skin bleeding test. and sustained inhibition of both collagen-induced aggregation and the second wave of ADP-induced 12-HETE production by platelets or whole blood in response to collagen is inhibited by aspirin, but aggregation of platelets ex vivo, and extension of skin bleeding time by a maximum factor of about appears to recover within a few hours.22,23 Platelet 12-LO activity appears to be susceptible to inhibition 2.5.11-13 In 'poor responders'14 5-10-fold greater doses may be required to see an effect, and there by aspirin in some individuals and not in others, 8 and it has been suggested that in those individuals are some individuals who seem not to respond even at higher doses. Hawkey et al.15 have shown that in in whom it is not inhibited but COX-1 is, excess arachidonic acid may be shunted down the pathway healthy subjects bleeding from the gastric mucosa in response to a standard insult (biopsy) is increased by to 12-HETE giving rise to enhanced haemostatic or thrombotic tendencies. There is some evidence that aspirin ingestion, with no difference between 300 mg od and 600 mg qds dosing, while McGurk and patients who have a good bleeding time extension in response to aspirin have better therapeutic Dinsdale16 have shown that the frequency of vacuum-induced petechiae on oral mucosa is not responses:14 this distinction has been built into the BRAT study, the results of which are awaited. On increased at 12 h after a single 325 mg dose. In both studies, skin bleeding times were significantly the other hand, Gimple and colleagues24 have found strong evidence that extended bleeding time is increased.
These pharmacodynamic actions, which are much strongly correlated with increased spontaneous bleeding after fibrinolysis following myocardial greater than those induced by salicylate or other non-steroidal anti-inflammatory agents (NSAIDs), infarction. It may be that the antithrombotic and prohaemorrhagic effects of aspirin run strictly in parallel. derive from aspirin's unique chemical action as an affinity label,17 transferring its acetyl group to the Ser529 residue of the constitutive cyclo-oxgenase (prostaglandin H synthase) type 1 enzyme (COX-1), Side-effect profile leading to complete and irreversible inactivation of the enzyme.18 The equivalent residue on the isozyme, The daily dose of aspirin required required for thromboprophylaxis is much lower than that needed COX-2 (which is constitutive at low activities in most cells including platelets19 but which is inducible for effective relief of pain or inflammation. Salicylates, and particularly aspirin, are still widely to high activities in inflammatory cells and some somatic cells during the inflammatory reaction) is used in high doses (>2 g/day) as analgesics, and have long been known to cause a variety of sidemuch less efficiently acetylated. However, high concentrations of salicylic acid reversibly inhibit COX-2, effects,25,26 particularly tinnitus, the classic symptom of salicylism, and (in common with most other explaining its anti-inflammatory, analgesic and febrifuge activities. Accumulated high concentrations of NSAIDs), a range of symptoms and metabolic derangements which may be severe enough to be salicylate can also block aspirin access to the Ser529 site of COX-1, but the practical importance of this lethal (detailed in Martindale27, pp. 17 et seq. and 72). All these unwanted effects are the result of is not clear.20 PGH 2 is metabolized in platelets entirely to thromboxane A 2 (Tx-A 2 ), a powerful excessive chronic use or overdosing. For the pharmacokinetic reasons given above, the side-effect profile platelet aggregator which mediates collagen-induced aggregation, the platelet release reaction and the of aspirin necessarily includes that of salicylic acid, although at the dosages now commonly employed second phase of ADP-induced aggregation. In vascular endothelial cells, PGH 2 is metabolized largely to for thromboprophylaxis (<300 mg/day) this does not present clinical problems. prostacyclin (PGI 2 ) a powerful inhibitor of platelet aggregation which also can cause disaggregation of
The mechanisms associated with aspirin toxicity are, in contrast to its antithrombotic action, still against the benefit of aspirin in preventing or deferring life-threatening infarction, stroke or pulmonary controversial. Aspirin, in common with salicylate and most other NSAIDs, has been associated with embolism. gastric mucosal irritation and erosions with microscopic blood loss, progressing to ulceration and frank, even catastrophic, bleeding into the gut at any showed that aspirin use significantly increases the risk of severe gastrointestinal upset or bleeding by of events in these situations. The answer is by no means complete, but we shall examine three types odds ratios ranging from 1.5 to 2.0, the increase being independent of narrow sub-category of event. of data, namely from randomized clinical trials, from case-control and similar studies, and from direct Similar odds ratios were obtained for minor gastric symptoms, whether leading to cessation of treatment experimental examination.
Haemorrhage is the most clinically important sideor not. Death as a result of gastrointestinal bleeding was very rare. Peptic ulcers were reported 30% more effect of aspirin use. Individual clinicians vary widely in their perception of how frequently this occurs.
frequently by aspirin takers (odds ratio about 1.3) but this estimate was very heavily influenced by data Commonly, individuals who have a history of dyspepsia or peptic ulceration are not prescribed longfrom one study. Roderick and colleagues showed further that, for each type of gastrointestinal event term aspirin to reduce vascular occlusion, either in routine practice or in clinical trials. The proportion considered-all bleeds, all symptoms and treatment cessations due to symptoms-the odds ratios for of patients who may be intolerant due to dyspepsia is uncertain, anecdotally between 5 and 25%.
dosing with 300 mg/day or less were consistently lower than for dosing with >300 mg/day, though However, even in the remainder there is the small chance that some severe bleeding, such as intracranever significantly different. The limited data on doses currently favoured for thromboprophylaxis nial haemorrhage or major gastrointestinal haemorrhage, might cause early disability or death. In each (40-150 mg/day) could not show whether gastrointestinal toxicity might be even less with these lower clinical context, such events must be balanced less than half of these events are directly attributable to aspirin use. These disadvantages are outweighed Examination of the more recent studies (Tables 2 to 5) confirms that adverse events are rarely defined by the benefits ( Table 6 ), confirming that all patients at high risk of vascular thrombotic events should be and recorded with the objectivity accorded to outcome events, although a recent study found the given aspirin unless there is a strong contraindication. It must be remembered also that the vascular events distinction between major and minor bleeding episodes to be reproducible and clinically relevant. 37 averted by aspirin are, in terms of quality-adjusted life years, far more serious than the vast majority of The WHO nomenclature of side-effects38 is rarely used, so exact comparisons between trials are diffithe haemorrhagic effects attributable to aspirin. cult, and even the methods of ascertainment are not consistent between trials. In general, questionAspirin and surgical bleeding naires39,40 and frequent direct questioning of in-patients in short-term studies will produce more Part III of the second round APTC overview33 gives some information on peri-and post-operative bleedfrequent records of more trivial events,41 while pragmatic reliance on the patient actively complaining ing complications. The need for transfusion of peri-operative bleeds was 7/1000 patients in the antimay miss minor events. Clearly, the potential toxicity of aspirin in the general population is greater than platelet treated groups (mostly aspirin) and 4/1000 patients in the control groups, based on up to 4000 that reported in clinical trials, since candidate trial subjects with gastrointestinal symptoms have usually patients in each group. The data in Table 7 suggest an increase of peri-operative blood loss of about been excluded: however, this exclusion mirrors clinical practice where patients complaining of such 30% (or about half a standard deviation) in patients taking aspirin in the 7 days before surgery. This may symptoms will not be prescribed aspirin.
Data published since the second round APTC be controlled by aprotinin42-44 or vasopressin45-49 treatment, by inhibition of fibrinolysis or increasing overview34 (Table 3 ) broadly confirm and extend the Factor VIII levels.50 Surgeons are concerned about intra-operative as well as post-operative bleeding, Diffuse bleeding was much more frequently associated with requirement for further intervention, wound infection and longer hospital stays and higher costs. Gavaghan, Gebski and Baron56 comment that of seven re-operations in 237 coronary artery bypass graft patients, five (1 placebo; 4 aspirin) had point source vessel bleeding and two had diffuse bleeding (both aspirin). In future studies, it would seem worthwhile attempting to distinguish between bleeding from vessels not surgically closed (silk deficiency) and diffuse (capillary) bleeding. Aspirin is often given post-partum or after dental surgery for pain control, but bleeding complications have not been recorded in large comparative trials. Reports which appear to have been influential in persuading some dentists to require cessation of aspirin before extractions are both old and, being based on rather small numbers, anecdotal:57-59 however, in these studies, pre-operative aspirin which caused moderate increase of the bleeding time did not cause any appreciable increase in peri-operative blood loss. In a case-control study of re-operation rates
Intracranial bleeding
in CABG patients, Bashein et al. 64 report that patients Intracranial bleeds (haemorrhagic strokes and ruptaking aspirin within 7 days prior to surgery have a tured aneurysms) are clinically the most important re-operation rate 1.82 (1.23-3.32) times higher than complications. A wide range of absolute rates of non-aspirin-takers. The authors comment that this intracranial haemorrhage in aspirin-treated groups is complication entails longer intensive care and genevident in the small studies from the second round eral hospital residence as well as increased use of APTC overview31 and trials published subsequently blood products, and that aspirin in the pre-operative (Table 4 ). Other than in the immediate postperiod should be avoided, if possible. Bischof et al.65 ischaemic-stroke period, the rates seem to be small, concluded from a long-term retrospective follow-up around 1 per 1000 patient years of exposure: less study on a 292 patients that, while life-long aspirin than half of these events are attributable to aspirin.
use might slightly prolong median survival time in In the immediate post-ischaemic-stroke period the carotid endarterectomy patients, it did not cause any rate will also include haemorrhagic conversion of detectable increase in intracranial haemorrhage. the original ischaemic stroke. The rate is about Otley et al.66 concluded from a retrospective series 10/1000 patients treated during 2-4 weeks60, 61 and a review of the literature that the excess of (seeming to be rather more than 10 times higher haemorrhagic complications following minor cutanethan in long-term use), but only between 7 and 20% ous surgery in patients taking aspirin was minimal. of these events may be attributable to aspirin.
The case-control study information shows some sort of consensus on risks for the gastrointestinal complications of aspirin use.67-73 The incidence of Case control and other studies clinically evident gastric, though possibly not peptic, ulcer is increased by a factor of about 1.3 times: 69, 70 In addition to randomized trials involving aspirin, the risk of perforation of an existing ulcer is increased many, mainly small, observational studies have been more. The risk of gastrointestinal bleeding severe published from which it is difficult to calculate enough to bring the patient to hospital appears haemorrhagic rates, although they generally accord enhanced by a factor between 1 and 10 times, with the randomized studies. Amongst such studies, perhaps depending on the formulation of aspirin, the Taggart, Siddiqui and Wheatley62 note that summary dose taken and the prior duration of use. In one figures are always distorted by outliers (heavy informative study,72 two series of controls were bleeders), even in the no-treatment group: this is a collected, one from the general community and the good reason for using medians (as has been done in other from hospital in-patients (excluding those  Tables 3 and 4 , above) and interquartile or 90% admitted with acute MI). It was clear that aspirin use ranges to summarize data with a wide distribution, correlated with hospitalization for all reasons other rather than the seemingly ubiquitous mean (SD). The than MI, yet the only causal relation inferred from experience of different surgical teams varies widely, this data was for gastrointestinal bleeding. But Weil and few investigators set out rigid criteria for et al. 72 found that 75% of ulcer bleeds admitted re-operation in the study protocol. It is interesting
were not associated with aspirin use. In brief, patients that Reich et al.63 reported no re-operations for who are ill enough to be hospitalized take aspirin bleeding in 197 consecutive patients undergoing more frequently than healthy controls. If a section coronary artery bypass grafting (CABG), approxiof the population has a medical condition that mately half of whom were taking aspirin, giving an predisposes both to the adverse event and to taking estimated maximum rate in the aspirin group well below any listed in Tables 7 and 8. the drug, drug-takers would be over-represented in Placebo, placebo-controlled trials; Other, trials involving other antiplatelet agents as comparator; trials, number of trials providing data; patients, number of patients treated with aspirin. * Two fatal bleeds recorded in aspirin groups, none in control groups. 73 production may recover quickly, the utility of the concept of sparing prostacyclin production by use of low doses of aspirin has still to be proven
Experimental studies
experimentally and clinically. The relatively large aspirin dose of 1200 mg/day is neither more nor less The two main questions addressed by experimental effective in reducing thrombosis than currently studies have been (i) what is the dose of aspirin that recommended regimens of 40-75 mg/day or every provides adequate inhibition of platelet function but other day. preserves prostacyclin and beneficial prostaglandin production; (ii) what are the mechanisms of gastric damage and microscopic blood loss?
Gastrotoxicity
Three mechanisms might lead to a causal relationship Aspirin dose and formulation between aspirin taking and increased gastrointestinal microhaemorrhage, viz. inhibition of platelet Many studies have correlated the dose, formulation and frequency of aspirin given with the surrogate aggregation; inhibition of cytoprotective mucosal prostaglandin synthesis and physical damage to the measure of inhibition of platelet aggregation. There appear to be 'good' and 'poor' responders, who luminal surface of the mucosa. It is difficult to separate the effects of these mechanisms. Platelet possibly represent extremes of a wide inter-individual variation, but who may be representatives of distinct aggregation is effectively inhibited by quite low doses of aspirin, as noted above. Hawkey and coworkers15 but overlapping populations. In good responders, whether normal volunteers or patients, a daily dose have shown that a moderate dose of aspirin (300 mg/day) effectively suppresses gastric mucosal of 40 mg or more causes, after 4 days, strong inhibition of collagen-or ADP-induced aggregation PGE 2 production. Local physico-chemical irritation, with or without suppression of the secretion of the ex vivo and extension of skin bleeding time by a maximum factor of about 2.5. In some poor respondprotective mucosal mucus-bicarbonate coat, by aspirin (or other non-steroidals) gives rise to erosions, ers, 5-10-fold greater doses may be necessary to prolong bleeding time. Some investigators suspect and possibly causes-certainly exacerbates-peptic or duodenal ulcers,15,67-70,88-91 and accelerates the that the dose-effect relation is less straightforward than indicated here.12, 74 Rodgers and Levin75 have shedding of mucosal cells into the gut lumen.92 Beyond these points, the literature is inconclusive critically reviewed the literature on bleeding times, and found that many accepted statements have little and sometimes contradictory, particularly regarding the influences of aspirin dose and formulation (standfactual support. Interpretation is bedevilled by the technical variations in even the so-called standard ard, soluble, enteric coated or intravenous), and the presence of pre-existing gastrointestinal pathology on bleeding times,76 in addition to biological variation: for instance, Frith and Warlow77 found no bleeding the source, amount and time-course of blood shedding into various segments of the gastrointestinal time difference between aspirin-and placebo-takers in a long-term treatment study. We need more tract.13,15,70,93-103 In summary, it appears that both an effect on information on the true status of apparent responders and non-responders, since improvement of the riskarachidonate metabolism and physical breakdown of the mucosal protective layer are required for large benefit balance can only come about by using the optimum dosage of drug in each individual.
increases in microhaemorrhage from normal gut.15 Although controlled-release formulations give minThere has been great interest in preserving cyclooxygenase (COX-1) activity in vascular endothelium imal systemic bioavailability of aspirin79 and may reduce systemic effects on mucosal prostaglandin and in the kidney,78 while obtaining full inhibition in platelets.79-84 Limited success may have been synthesis, no oral presentation (except, perhaps, sublingual104) can avoid local inhibition at the site achieved with low doses, particularly in enteric coated and controlled release formulations, and of uptake of the active drug through the gut wall. Standard or soluble aspirin increases the frequency perhaps with reduced dose frequency. However, Kyrle et al.85 have shown that doses of ordinary of gastric erosions, but this is probably without clinical significance: however, in the presence of aspirin as low as 35 mg/day can at 2 h after last dose prevent prostacyclin (measured as PGF 1a ) proother predisposing factors (e.g. H. pylori infection), aspirin may increase the likelihood that erosions duction in bleeding time incision blood, as well as thromboxane production in both in clotting blood progress to peptic ulcers. Thus, aspirin increases gastrointestinal haemorrhage largely only when re-operation to stop bleeding or to drain operation site haematomas. The balances of risk and benefit major lesions or other pathology are present.
are close in all cases. Some authors have advocated stopping aspirin at least 5 days before elective operations so that the patient's haemostatic mechan-
Risk and benefit
isms have returned to normal before operation: the
Arterial disease
gain in safety is balanced by exposure of the patient to possible thrombosis. On balance, we find no Aspirin is an important drug which can reduce convincing argument either way, but feel it is likely vascular mortality and morbidity. It is now standard that the excess rate of operation site complications clinical practice to use aspirin after acute myocardial attributable to aspirin is more than balanced by the infarction, when, in the short term, the risk of less reduction in thrombotic complications: we suggest than one bleeding episode of any kind is outweighed that aspirin treatment is continued. There is no good by approximately 40 major vascular events averted.
evidence that aspirin use pre-operatively leads to The advantages in acute stroke management are any excess subdural bleeding when regional anaessmaller, but worthwhile. The reduction of all cause thesia is used. A large trial, the Pulmonary Embolus mortality by about 5 and of recurrent stroke by about Prevention (PEP) Trial is in progress to determine the 8 per 1000 patients treated must be balanced with balance of benefit (in preventing arterial and venous an increase of about two haemorrhagic strokes and thrombosis) and risk (including haemorrhage) comfour major extracranial bleeds per 1000 patients.60, 61 pared to placebo of 162 mg of enteric coated aspirin The consensus from major clinical trials of aspirin given daily from pre-operatively for 5 weeks in about concerning long-term use (Table 6 ) is that 1000 patients 14 000 patients undergoing surgery for fractured neck have to be treated for 1 year to prevent 15-20 fatal of femur:106 the results are expected in early 1999. or non-fatal vascular events. Thus, it is very reasonable to recommend long-term dosing in high-risk patients,
Perspective
for whom there is an approximate trade-off of [5] [6] [7] The clinical benefits of aspirin may be put into major vascular events prevented, about one-third fatal, perspective by comparing it to fibrinolytic therapy for every attributable major gastrointestinal bleed, after myocardial infarction, which is justifiably seen which is most unlikely to be fatal.
as a dramatic, life-saving treatment. The Fibrinolytic The efficacy of, and indications for, a drug are Therapy Trialists' Collaborative Group,107 after determined by the absolute, rather than the proporreviewing all fibrinolysis trials of over 1000 patients tional, number of clinical events avoided by its use.
concluded that an excess of 3.9±0.8 strokes and By this criterion, aspirin has an important role, since 7.3±0.7 major bleeds per 1000 patients treated was it reduces morbidity and mortality in vascular disan acceptable trade-off for the 18±3 deaths avoided ease, which is common. In contrast, in people at in the immediate post-infarct period. The risk-benefit low risk of vascular events, the balance of risk and ratio for aspirin in long-term thromboprophylaxis benefit is even, fewer than one event being avoided estimated by Roderick, Wilkes and Meade34 appears for each major bleed. In the US physicians trial105 even more favourable; between 0.2 and 8 attributable the increased risk of intracranial haemorrhage outadverse events are offset by 2-10 deaths plus 4-20 weighed the very minor absolute benefit of reduction serious non-fatal vascular events deferred per 1000 of myocardial infarction and stroke. The benefit was patient-years of exposure to any dose of aspirin. Of minor not because aspirin was less effective in giving more importance, only a very small proportion of a proportional reduction in vascular events, but the attributable haemorrhagic events, specifically because the population studied was at extremely intracranial haemorrhage and severe gastrointestinal low risk of developing vascular events. In such bleeding, are potentially disabling or fatal. Thus, the circumstances, it is probably not wise to recommend perception amongst clinicians, and the general aspirin treatment for primary prevention.
public, that low-dose aspirin is an inexpensive and relatively harmless drug which provides meaningful Surgery, deep-vein thromboses and benefits in reducing vascular disease is broadly correct.108 The use of low-dose aspirin is recompulmonary embolism mended for all groups of people with an increased There is evidence from overviews that pre-operative risk of thrombosis. or immediate post-operative aspirin use may reduce significantly the rates of both early and late occlusion of vascular grafts. It may also reduce the risk of both Conclusions post-operative deep vein thrombosis (by about 25%) and embolism (fatal plus non-fatal by about 60%). 33 Aspirin use significantly reduces the risk of vascular morbidity and death. Benefit can be obtained with However, aspirin may also increase the need for 
